(Skip to Content)
 
Fistula First For Patients For Clinical Staff News Bulletins Home
Facility Lists Complaints & Grievances Job Postings Resources & Links Who We Are
Emergency Preparedness Consumer News Quality Improvement ESRD NCC Annual Reports
Summary Statistics Privacy Policy Data Forms Conditions for Coverage Contact Us
    FDA Alerts    
end of menus

logo    
Northwest Renal Network

News Bulletins 2010
Part III - July through September

end of header

  Topic Index  

 
    LATER BULLETINS
30 Sep 2010
    Washington State Only: New HCA Drug Administration Rules
30 Sep 2010
    NKF Renal Education Conference October 24 in Portland
27 Sep 2010
    Mid-Columbia Nephrology Seminar October 17
26 Sep 2010
    Specific Lots of Epogen and Procrit Recalled
26 Sep 2010
    Free NANT Webinar with Contact Hours; NANT Webinar Series and March Symposium
23 Sep 2010
    Acute Dialysis 2010 ANNA Professional Meetings October 5 and 13
23 Sep 2010
    Avandia (rosiglitazone) Usage Restriction
23 Sep 2010
    DFR Summary 2010 Added to Website
22 Sep 2010
    Access Documents Updated
22 Sep 2010
    AVF Progress
21 Sep 2010
    Psychosocial Tools Web Page Updated
20 Sep 2010
    Open Door Forum on HIPAA 5010
20 Sep 2010
    Actos (pioglitazone) FDA Safety Review
15 Sep 2010
    Possible Overdose in Pediatric Patients: Valcyte (valganciclovir hydrochloride) Label Change
14 Sep 2010
    Patients: Impact of New Medicare Billing Process
13 Sep 2010
    Free Patient Education Conference Calls on Diabetes and Communication
12 Sep 2010
    Hospira Symbiq Infusers Class I Recall
10 Sep 2010
    New Patient Newsletter on Coping with Your Concerns
10 Sep 2010
    National Emergency Preparedness Education Week September 19-25
10 Sep 2010
    Fresenius Hemodialysis Machine Power Cord Recall
10 Sep 2010
    Gadolinium-Based Contrast Agents Labeling Change
7 Sep 2010
    Tygacil (tigecycline) Label Change
28 Aug 2010
    Warning on Fingerstick and Blood Testing Devices
24 Aug 2010
    Seattle RSN Meeting Location Change
19 Aug 2010
    CMS Open Door Forums on Quality Incentive Payment and on ICD-10/5010
16 Aug 2010
    Proposed Midodrine Hydrochloride (ProAmatine) Approval Withdrawal
3 Aug 2010
    NKF Kidney Walk in Anchorage September 25
3 Aug 2010
    NKF Educational Symposium near Portland September 19
3 Aug 2010
    Renal Support Network Lifestyle Meeting near Seattle August 29
23 Jul 2010
    June 2010 Patient Census (Modality Reports)
23 Jul 2010
    Involuntary Discharge Notification Requirements
22 Jul 2010
    ANNA Hemodialysis Workshop September 12 in Seattle
19 Jul 2010
    2009 Network Annual Report Posted
17 Jul 2010
    Cincinnati Vascular Access Symposium October 1-2
17 Jul 2010
    Blood Pressure Meds FDA Safety Review
15 Jul 2010
    Limited Coumadin Recall
10 Jul 2010
    Jobs Page on Network Website Updated
10 Jul 2010
    2000-2008 Network Annual Reports Restored
10 Jul 2010
    New CROWNWeb Links
9 Jul 2010
    Proposed Revisions to HIPAA Privacy/Security/Enforcement Rules
9 Jul 2010
    New Qualaquin (Quinine) Medication Guide
2 Jul 2010
    Physio-Control LIFEPAK 20/20e Defibrillators Class 1 Recall
      EARLIER BULLETINS

  Topic Index  

end of bulletin list; bulletin content follows

September 30, 2010
Washington State Only: New HCA Drug Administration Rules
The State of Washington has adopted new rules for drug administration by Health Care Assistants.   Details can be found at http://www.nwrenalnetwork.org/N/1019044hca103final.pdf.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 30, 2010
NKF Renal Education Conference October 24 in Portland
There are later articles on Professional Meetings.
The National Kidney Foundation is sponsoring the Northwest Conference on Renal Education, to be held October 24, 2010 in Portland OR.   Registration is open to nurses, dieticians, social workers, PCTs, and other allied health professionals.   The conference will provide seven continuing education hours/units.   Topics include allograft failure, metabolic bone disease, herbal medicine, fluid management, palliative care, peer mentoring, buttonhole cannulation, and patient perspectives.   For details see http://www.nwrenalnetwork.org/N/NWCORE10.pdf.   There are earlier articles on Professional Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 27, 2010
Mid-Columbia Nephrology Seminar October 17
There are later articles on Professional Meetings.
The 7th Annual Mid-Columbia Nephrology Seminar, for all nephrology professionals, will be held in Richland WA on October 17, 2010.   Topics include Maximizing AV Fistulas, Dialysis Basics, Survey Preparedness, Renal Transplant: Surgical Aspects, and Disaster Preparedness.   The registration fee includes breakfast, lunch, and 9 hours of CEUs.   For details see http://www.nwrenalnetwork.org/N/MidColumbia2010.pdf.   There are earlier articles on Professional Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 26, 2010
Specific Lots of Epogen and Procrit Recalled
There are later articles on EPO Use.
Amgen is recalling several hundred different lots of Epogen and Procrit (epoetin alfa) because they may contain barely-visible glass flakes which could produce potentially serious adverse events when injected.   The recall includes a number of different packaging configurations and dosages.   The list of packagings/dosages/lot numbers can be found at http://www.fda.gov/Safety/Recalls/ucm227202.htm (scroll down to the bottom of the page).   The FDA Safety Notice is at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm227225.htm.   The FDA notice says that Amgen has initiated recall letters which include return instructions.   There are earlier articles on EPO Use.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 26, 2010
Free NANT Webinar with Contact Hours; NANT Webinar Series and March Symposium
There are later articles on Professional Meetings.

The National Association of Nephrology Technicians/Technologists ("NANT") is providing a free online seminar ("Webinar"), with free contact hours, on October 14.   The Webinar is in honor of National Technician Recognition Week, and will cover recent and upcoming changes in dialysis, including the new Conditions for Coverage, and the proposed payment "bundling."   Full details can be found at http://www.nwrenalnetwork.org/N/NRW2010.pdf.   To attend and receive contact hours, you must register before October 12, at http://www.nant.biz/store/index.php/cName/webinars.

While not free, NANT is also presenting additional Webinars on "Urea from Food to Floor Drain" (September 29), the "Role of the Inanimate Environment" (October 6), "Hepatitis C" (October 20), and "CDC Infection Control Guidelines" (October 27).   Registration must be completed before the Tuesday prior to each Webinar, at http://www.nant.biz/store/index.php/cName/webinars.

The 2011 NANT National Symposium will be held March 8-10, 2011 in Las Vegas.   For information, see http://www.nant.biz/store/index.php/cName/symposium-registration-2011.

There are earlier articles on Professional Meetings and on Patient Care Technicians.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 23, 2010
Acute Dialysis 2010 ANNA Professional Meetings October 5 and 13
There are later articles on Professional Meetings.
ANNA Chapter 503 will sponsor the Acute Dialysis 2010 professional meetings in Seattle on October 5, and again with the same agenda on October 13.   Topics include Updates in Acute Dialysis, Infection Control in Hemodialysis, and Withdrawing and Withholding Dialysis.   ANNA will provide 3 contact hours.   The meetings are free, but registration is required.   For details see http://www.nwrenalnetwork.org/N/AcuteUW2010.pdf.   There are earlier articles on Professional Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 23, 2010
Avandia (rosiglitazone) Usage Restriction
There are later articles on Actos/Avandia and on Diabetes.
The FDA has announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone), in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.   Rosiglitazone also is available in combination with other medications under brand names Avandamet and Avandaryl.   Avandia will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take Actos (pioglitazone).    Current users of Avandia who are benefiting from the drug will be able to continue using the medication if they choose to do so.   For details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm.   For recent news on Actos, see http://www.nwrenalnetwork.org/news_bulletins10C.htm#act9j.   There are earlier articles on Actos/Avandia and on Diabetes.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 23, 2010
DFR Summary 2010 Added to Website
There are later articles on Quality Improvement and on Dialysis Facility Reports.
We've added to the Network website a summary, by state, of the 2010 Dialysis Facility Reports.   Find it at http://www.nwrenalnetwork.org/S/statsdfr.htm.   There are earlier articles on Dialysis Facility Reports and on Quality Improvement.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 22, 2010
Access Documents Updated
There are later articles on Vascular Access.
We've updated two vascular access articles on the Network website: "Preparing the Vascular Access for Cannulation" at http://www.nwrenalnetwork.org/fist1st/cleanaccess.pdf and "The Importance of Washing Your Access" at http://www.nwrenalnetwork.org/washyouraccess.pdf.   These documents are posted under "On Course with Cannulation Tools and Resources for Dialysis Staff" in our Fistula First section, at http://www.nwrenalnetwork.org/fist1st/ffcannu.htm.   There are earlier articles on Vascular Access.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 22, 2010
AVF Progress
There are later articles on Vascular Access.
We've posted the Network's June AVF rates at http://www.nwrenalnetwork.org/fist1st/fist1st.htm#progress.   Keep up the good work - we're within one percentage point of our 66% AVF-in-use goal for prevalent patients!   We're still getting AVFs placed in only 40% of incident patients, however, compared to our 60% goal.   Counting only facilities with five or more incident patients, fifteen facilities from a wide variety of locations and ownership/management structures *did* meet the incident-patient goal in 2009, so we know 60% is a reasonable goal.   Now we just need to get everyone else to 60% AVF for incident patients.   There are earlier articles on Vascular Access.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 21, 2010
Psychosocial Tools Web Page Updated
There are later articles on Patient Assessment and Care Plan.
We've updated our web page on Psychosocial Tools and Resources for Assessing Patients.   Find the new page at http://www.nwrenalnetwork.org/SW/PsychosocialTools.pdf.   There are earlier articles on Patient Assessment and Care Planning.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 20, 2010
Open Door Forum on HIPAA 5010
There are later articles on Reimbursement, on HIPAA, and on Medical Records.
On September 29, CMS will hold its "Tenth National Education Call on Medicare Fee-For-Service (FFS) Implementation of HIPAA Version 5010 and D.0 Transactions: Medicare FFS 5010 Program: Taking EDI to the Next Level."   For details see http://www.cms.gov/OpenDoorForums/15_ODF_ESRD.asp.   There are earlier articles on HIPAA, on Medical Records, and on Reimbursement.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 20, 2010
Actos (pioglitazone) FDA Safety Review
There are later articles on Actos/Avandia and on Diabetes.
The FDA has announced an ongoing safety review to evaluate whether Actos (pioglitazone) is associated with an increased risk of bladder cancer.   Findings from studies in animals and humans suggest a potential safety risk that needs further study.   FDA review is ongoing, and the FDA will provide additional information when it is available.   For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226257.htm.   There are earlier articles on Actos/Avandia and on Diabetes.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 15, 2010
Possible Overdose in Pediatric Patients: Valcyte (valganciclovir hydrochloride) Label Change
The FDA has changed labeling of the antiviral Valcyte (valganciclovir hydrochloride) to set an upper limit on dose in pediatric patients with low body weight, low body surface area, or below normal serum creatinine.   For details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm225888.htm.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 14, 2010
Patients: Impact of New Medicare Billing Process
There are later articles on Paying for Treatment and on Reimbursement.
Medicare is changing the way it reimburses dialysis providers, and on September 21, the Centers for Medicare Services (CMS) is offering a telephone workshop for patients, families, and advocates, on how these changes will impact patients.   CMS calls the changes their "Quality Incentive Program" (QIP), and their objective is to pay more for better care than they do for substandard care.   The workshop (which CMS calls an "Open Door Forum") will explain the changes, and give instructions on how to provide feedback to CMS on the changes.   For full details, see http://www.cms.gov/OpenDoorForums/15_ODF_ESRD.asp.   There are earlier articles on Patient Empowerment, on Paying for Treatment, and on Reimbursement.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 13, 2010
Free Patient Education Conference Calls on Diabetes and Communication
There are later articles on Patient Empowerment, on Patient Meetings, on Patient Education, and on Diabetes.
The National Kidney Foundation's People Like Us program is sponsoring a 90-minute conference call for patients on "Communicating with Your Healthcare Team" September 21, 2010.   The call is free, but you'll need to register ASAP, because the number of phone lines is limited.   Find complete information at http://www.kidney.org/coffeehouse/topic3.cfm, and a lovely poster for posting at dialysis or other healthcare facilities, at http://www.nwrenalnetwork.org/N/nkfcoffeecomm.pdf.   The call will be recorded and rebroadcast October 5.   The call is part 3 of the NKF Coffee House Conversations series on "Diabetes: Your Actions Can Make a Difference."   Part 2 was on "What You Need to Know About Diabetes and Your Kidneys," and will be rebroadcast September 19 and September 29; for details see http://www.kidney.org/coffeehouse/topic2.cfm.   Part 1 was on "Why Managing Blood Sugar Is So Important: What You Can Do and What Your Healthcare Provider Can Do."   You can listen to a recording of part 1, and find information about the series in general, at http://www.kidney.org/coffeehouse/.   There are earlier articles on Patient Education, on Patient Meetings, on Patient Empowerment, and on Diabetes.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 12, 2010
Hospira Symbiq Infusers Class I Recall
There are later articles on Infusion Devices.
The FDA has announced a Class I recall of Hospira Symbiq One-Channel and Two-Channel Infusers because of potential for the device to fail to detect air in the line at the end of an infusion.   Failure to detect air in the line may result in delivery of air to the patient's blood, resulting in serious injury or death.   For details and recall instructions, see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm225516.htm.   There are earlier articles on Infusion Devices.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 10, 2010
New Patient Newsletter on Coping with Your Concerns
There are later articles on Patient Empowerment and on Network Consumer News.
Volume 4 Issue 1 of the patient newsletter Network Consumer News has been mailed to facilities for distribution to patients. &nbap If you haven't seen a copy, ask your dialysis facility for one, or contact the Network. &nbap This issue is on "Keys to Coping with Your Concerns."   It includes:

           A packet of information on National Emergency Preparedness Education Week for Kidney Patients (see http://www.nwrenalnetwork.org/news_bulletins10C.htm#emer9d);
           A handout on how to get Free Educational Materials;
           A flyer on the September 19 Portland NKF Patient & Care Partner Education Symposium (see http://www.nwrenalnetwork.org/news_bulletins10C.htm#nkf8b); and
           A word search puzzle on Keys to Coping with Your Concerns.

For links to the online versions of the newsletter and the inclusions, see http://www.nwrenalnetwork.org/P/NCN.htm#ncn41.   There are earlier articles on Network Consumer News and on Patient Empowerment.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 10, 2010
National Emergency Preparedness Education Week September 19-25
There are later articles on Emergency Preparedness.
September 19-25, 2010 is National Emergency Preparedness Education Week, and we've added supporting material to the Network website at http://www.nwrenalnetwork.org/E/emergency.htm#fac, including a poster, a four-page manual from the Kidney Community Response Coalition (KCER, http://www.kcercoalition.com/) on "Preparing for Emergencies for Dialysis Patients," a one-page "Dialysis Patient Disaster Survival Guide" flyer, and a "Patient Disaster Drill Questionnaire," also from KCER.   The documents are written for facilities to provide to patients, but patients should not hesitate to help themselves.   The documents were also distributed to facilities along with the August Network Consumer News (see http://www.nwrenalnetwork.org/news_bulletins10C.htm#ncn9e).   There are earlier articles on Emergency Preparedness.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 10, 2010
Fresenius Hemodialysis Machine Power Cord Recall
The FDA has announced a Class II recall for some AC power cords on Fresenius 2008K, 2008K2, and 2008K@home Hemodialysis Machines, Granuflo I Mixers, spare Main Power Supply Assemblies, and spare Power Cord Assemblies because of potential for sparking, charring, and fire.   For full details see http://www.fmcna.com/documents/Recall_Notification_AC Power Cord_Final_11-11-09 (L).pdf.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 10, 2010
Gadolinium-Based Contrast Agents Labeling Change
The FDA is requiring changes in the professional labeling for gadolinium-based contrast agents (GBCAs), including Ablavar (gadofosveset trisodium), Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), Multihance (gadobenate dimeglumine), Omniscan (gadodiamide), Optimark (gadoversetamide injection), and Prohance (gadoteridol), to minimize the risk of nephrogenic systemic fibrosis (NSF), a rare but serious condition associated with the use of GBCAs in patients with kidney dysfunction.   Patients at greatest risk for developing NSF after receiving GBCAs are those with impaired elimination of the drug, including patients with acute kidney injury or chronic, severe kidney disease. For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm225375.htm.   There are earlier articles on Gadolinium.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

September 7, 2010
Tygacil (tigecycline) Label Change
The FDA has identified increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to other drugs used to treat serious infection.   The increased risk was most prominent in treatment of pneumonia, but also seen in complicated skin, skin structure, and intra-abdominal infections, and diabetic foot infections.   The FDA has updated sections of the Tygacil drug label accordingly.   See http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm224626.htm for full details.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 28, 2010
Warning on Fingerstick and Blood Testing Devices
There are later articles on Diabetes.
Because of increases in bloodborne infection transmission among users of reusable fingerstick devices and other blood testing devices such as blood glucose meters, the FDA is warning against sharing these devices with other people.   For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm224135.htm.   There are earlier articles on Diabetes.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 24, 2010
Seattle RSN Meeting Location Change
There are later articles on Patient Meetings.
The August 29 RSN Seattle Patient Lifestyle Meeting in Federal Way (see http://www.nwrenalnetwork.org/news_bulletins10C.htm#rsn8a) has changed location.   The poster at http://www.rsnhope.info/programs/Regional%20Meetings/PLM_flyer_Seattle_2010.pdf has been updated to include the new location.   There are earlier articles on Patient Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 19, 2010
CMS Open Door Forums on Quality Incentive Payment and on ICD-10/5010
There are later articles on Medical Records and on Reimbursement.
CMS will hold Open Door Forums August 24 on “ESRD Quality Incentive Program Payment Year 2012: Proposed Rule Overview for Facilities, Providers and Suppliers,” and September 13 on “ICD-10 Implementation in a (HIPAA) 5010 Environment.”   For full details see http://www.cms.gov/opendoorforums/15_odf_esrd.asp?.   There are earlier articles on Medical Records and on Reimbursement.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 16, 2010
Proposed Midodrine Hydrochloride (ProAmatine) Approval Withdrawal
The FDA has proposed withdrawing approval for the drug midodrine hydrochloride, marketed as ProAmatine and generics, because required studies to verify clinical benefit have not been done.   The drug is used to treat the low blood pressure condition orthostatic hypotension.   The FDA recommends that Patients currently taking this medication should continue taking it while they consult their health care professional about other treatment options.   For details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm222640.htm.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 3, 2010
NKF Kidney Walk in Anchorage September 25
There are later articles on Patient Meetings.
The Alaska NKF is also presenting the Inaugural 2010 Anchorage Kidney Walk on September 25, 2010.   Find complete details at http://donate.kidney.org/site/TR/Walk/NorthernCaliforniaNorthernNevadaOregonWashingtonandAlaska?pg=entry&fr_id=3140.   There are earlier articles on Patient Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 3, 2010
NKF Patient & Care Partner Educational Symposium near Portland September 19
There are later articles on Patient Meetings and on Patient Education.
The National Kidney Foundation’s Fall 2010 NKF Patient & Care Partner Education Symposium is scheduled for September 19, 2010, in Tualatin Oregon.   The topic is “Lessons in Living with Kidney Disease: Knowledge, Inspiration, & Support.”   Details can be found at http://www.nwrenalnetwork.org/N/NKFEd0910.pdf.   The event is free, but early registration is advised due to limited space.   There are earlier articles on Patient Meetings and on Patient Education.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

August 3, 2010
Renal Support Network Lifestyle Meeting near Seattle August 29
There are later articles on Patient Meetings.
The Renal Support Network is holding its Seattle Patient Lifestyle Meeting in Federal Way Washington, on August 29, 2010.   There is no charge for patients and one guest per patient.   Topics include Keeping Fit, Benefits of an Early Transplant, Spicing up Your Diet, “Going Rogue,” How Do I Ask for a Kidney?, Understanding Your Treatment Options, and Planning Your Course.   For details see http://www.rsnhope.info/programs/Regional%20Meetings/PLM_flyer_Seattle_2010.pdf.   Please register by August 20.   There are earlier articles on Patient Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 23, 2010
June 2010 Patient Census (Modality Reports)
There are later articles on Dialysis Census (Modality Reports).
We’ve received permission to once again post the Network’s Modality Reports, or quarterly unofficial Dialysis Patient Census.   We’ve posted the June 2010 Reports at http://www.nwrenalnetwork.org/modality/mode0610/modality.htm, and we’ll replace the historical information during August.   The June 2010 Modality Reports show growth of 6.2% in the Network dialysis population since last June, composed of 9.4% growth in Idaho, 7.2% in Oregon, 5.8% in Washington, 4.2% in Montana, and 1.2% in Alaska.   There are earlier articles on Dialysis Census (Modality Reports).

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 23, 2010
Involuntary Discharge Notification Requirements
There are later articles on Conditions for Coverage and on Conflict Resolution.
The Conditions for Coverage require all facilities to notify both the Network and your State Survey Agency, within specified time parameters, of all involuntary discharges and transfers.   We would like to remind facilities of the document Notifying the Network of Involuntary Discharges and Involuntary Transfers, available at http://www.nwrenalnetwork.org/G/Involuntary.pdf.   This document was created to assist dialysis facilities in complying with the requirements of the CfC and Survey Interpretative Guidelines.    It is also intended to assist facilities in understanding what the Network will be requesting in order for it to fulfill Network goals and the terms of its current CMS Contract.   There are earlier articles on Conditions for Coverage and on Conflict Resolution.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 22, 2010
ANNA Hemodialysis Workshop September 12 in Seattle
There are later articles on Vascular Access and on Professional Meetings.
The Greater Puget Sound Chapter #503 of ANNA will sponsor a Summer Hemodialysis Workshop on Sunday, September 12, 2010 from 8:30 am to 5:00 pm at Children’s Hospital, Seattle, WA.    Diana Hlebovy, BSN, RN, CHN, CNN, will be speaking on Fluid & Electrolyte Balance, and Lynda Ball, MSN, RN, CNN, will be speaking on Cannulation.   This program has been awarded 9.05 Contact Hours.   For more information, contact Nancy Colobong-Smith at 206-598-4442 or Lynda Ball at 206-923-0714 ext 111.   There are earlier articles on Professional Meetings and on Vascular Access.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 19, 2010
2009 Network Annual Report Posted
There are later articles on Network Annual Reports.
We've posted the 2009 Network Annual Report on the Network website at http://www.nwrenalnetwork.org/AR/ARS.htm.   There are earlier articles on Network Annual Reports.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 17, 2010
Cincinnati Vascular Access Symposium October 1-2
There are later articles on Vascular Access and on Professional Meetings.
The 2010 Cincinnati Hemodialysis Vascular Access Symposium will be held October 1 & 2.   The program is designed for surgeons, nephrologists, radiologists, residents, and dialysis nurses, technicians, and administrators.   The Symposium schedule, faculty, location, registration form, CME/CE information, and other details can be found at http://www.nwrenalnetwork.org/N/CinHDVA2010.pdf.   There are earlier articles on Vascular Access and on Professional Meetings.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 17, 2010
Blood Pressure Meds FDA Safety Review
The FDA has initiated an ongoing safety review of Angiotensin Receptor Blockers (ARBs) for cancer risk.   ARBs are used for high blood pressure and other conditions.   Brand names include Atacand, Avapro, Benicar, Cozaar, Diovan, Micardis, and Teveten.   The FDA has not concluded that ARBs increase the risk of cancer, but is reviewing information related to this safety concern and will issue recommendations when additional information is available.   The FDA believes the benefits of ARBs continue to outweigh their potential risks.   Healthcare professionals and patients are encouraged to report adverse events and side effects related to ARB use.   For details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm219185.htm.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 15, 2010
Limited Coumadin Recall
The FDA has announced that specific lots of Bristol-Myers Squibb Coumadin 1 mg tablet blister packs are being recalled because of possible dosage variation as the product ages.   Only the 1 mg tablet blister-packs are involved.   See http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm218955.htm for full details.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 10, 2010
Jobs Page on Network Website Updated
We've removed all job descriptions more than six months old from our Jobs page at http://www.nwrenalnetwork.org/jobs.htm.   If we removed a job of yours that's still open, just let us know (http://www.nwrenalnetwork.org/contact.htm), and we'll put it back.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 10, 2010
2000-2008 Network Annual Reports Restored
There are later articles on Network Annual Reports.
We've refreshed the Annual Report page on the Network website at http://www.nwrenalnetwork.org/AR/ARS.htm, with Network Annual Reports for 2000-2008.   We'll post the 2009 Network Annual Report in July or August, following CMS approval.   There are earlier articles on Network Annual Reports.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 10, 2010
New CROWNWeb Links
There are later articles on CROWNWeb.
We've replaced the CROWNWeb logo on the Network website with a new graphic.   The link from the graphic will be updated every few weeks, so that at any given time, clicking on the graphic (a blue box) will direct you to the latest CROWNWeb news.   If your security protocol does not allow Java scripts, you may need to temporarily enable them to see the graphic.   The graphic appears on our home page (http://www.nwrenalnetwork.org), Data Forms page (http://www.nwrenalnetwork.org/IM/IM.htm), Staff page (http://www.nwrenalnetwork.org/staff.htm), and Conditions for Coverage page (http://www.nwrenalnetwork.org/CfC/CfC.htm).   We've also added a few useful CROWNWeb links on our Data Forms page.   There are earlier articles on CROWNWeb.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 9, 2010
Proposed Revisions to HIPAA Privacy/Security/Enforcement Rules
There are later articles on HIPAA.
The HHS Office of Civil Rights ("OCR") is proposing new rules to implement changes, required by the HITECH Act, to HIPAA privacy, security and enforcement provisions.   Information on the proposed regulations can be found at http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/hitechnprm.html.    Comments are due within 60 days after the notice appears in the Federal Register.   OCR has also revised their Breach of Privacy procedures; see http://www.hhs.gov/ocr/privacy/hipaa/administrative/breachnotificationrule/breachtool.html for more information on this.   There are earlier articles on HIPAA.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

July 9, 2010
New Qualaquin (Quinine) Medication Guide
The FDA has mandated a new Medication Guide for Qualaquin (quinine sulfate) warning of possible serious adverse consequences from the off-label use of Qualaquin to manage night time leg cramps.   Qualaquin use may result in serious and life-threatening hematological reactions, including serious bleeding due to thrombocytopenia, and hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura, which in some cases may result in permanent kidney damage.   In some patients, adverse reactions result in hospitalization and death.   For full details, see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm218424.htm.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

June 18, 2010
Physio-Control LIFEPAK 20/20e Defibrillators Class 1 Recall
There are later articles on Defibrillator Recalls.
The FDA has announced a Class 1 recall of Physio-Control Inc.’s LIFEPAK 20 and LIFEPAK20e External Defibrillator/Monitors because they may fail to function.   For details, see http://www.fda.gov/MedicalDevices/Safety/RecallsCorrectionsRemovals/ListofRecalls/ucm217933.htm.   Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.   There are earlier articles on Defibrillator Recalls.

TOP OF PAGE     BOTTOM OF PAGE

end of bulletin

EARLIER BULLETINS

  Topic Index  

end of bulletins

Page updated October 11, 2011                 
end of content
Fistula First For Patients For Clinical Staff News Bulletins Home
Facility Lists Complaints & Grievances Job Postings Resources & Links Who We Are
Emergency Preparedness Consumer News Quality Improvement ESRD NCC Annual Reports
Summary Statistics Privacy Policy Data Forms Conditions for Coverage Contact Us
    FDA Alerts